Natesto

Not for use in women. History of nasal disorders, nasal or sinus surgery, nasal fracture within previous 6 months or one that caused a deviated anterior nasal septum, mucosal inflammatory disorders (eg, Sjogren’s syndrome), or sinus disease: not recommended. Increased risk for worsening BPH; monitor for signs/symptoms. Evaluate for prostate cancer before starting therapy, and 3–6 months after initiation. Monitor hematocrit prior to initiation, at 3–6 months after starting therapy, then annually; if elevation occurs, withhold until acceptable level. Preexisting cardiac, renal, or hepatic disease (discontinue if edema occurs). Discontinue and evaluate if signs/symptoms of hepatic dysfunction (eg, jaundice) occur. Possible sleep apnea in patients with obesity or chronic lung diseases. Testosterone and/or other anabolic androgenic steroid abuse. Monitor serum testosterone, PSA, liver function, cholesterol, lipid profile, serum calcium (in cancer patients at risk for hypercalcemia/hypercalciuria) periodically. Monitor for venous thromboembolism; discontinue if suspected. Inform patients of possible increased risk of MI, stroke. Consider alternative if total testosterone consistently <300ng/dL; discontinue if consistently >1050ng/dL. Monitor for nasal adverse reactions; discontinue if appropriate. Men with BMI >35kg/m²: not established. Elderly.